Who Paid My Doc
Edgar Torres Garcia
Endocrinology, Diabetes & Metabolism Cidra, PR Medical Doctor
NPI 1871741090 CMS profile 843452
Carr 172 Km 19.1, Eastern Consulting Group, Cidra, PR 00739
General payments
$16,866
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Edgar Torres Garcia of Cidra, PR is reported in the CMS Open Payments database as having received $16,866 across 341 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 83rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $482 | 21 | |
| 2024 | General | $574 | 18 | |
| 2023 | General | $2,846 | 56 | |
| 2022 | General | $1,236 | 50 | |
| 2021 | General | $2,353 | 59 | |
| 2020 | General | $1,199 | 59 | |
| 2019 | General | $8,177 | 78 |
Beside peers
- Edgar Torres Garcia
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Edgar Torres Garcia were reported at $482. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Edgar Torres Garcia | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,177 | $494 | $123–$2,253 | $163 |
| 2020 | $1,199 | $335 | $85–$1,841 | $114 |
| 2021 | $2,353 | $398 | $88–$1,981 | $132 |
| 2022 | $1,236 | $364 | $88–$1,568 | $149 |
| 2023 | $2,846 | $420 | $113–$1,614 | $160 |
| 2024 | $574 | $440 | $121–$1,646 | $164 |
| 2025 | $482 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 54 drugsPart D claims
4,778
Drug cost
$906,764
Branded share of claims
47.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 301 | $216,323 | |
| Ozempic Semaglutide | Brand | 164 | $161,564 | |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | Brand | 238 | $156,509 | |
| Trulicity Dulaglutide | Brand | 71 | $70,185 | |
| Xigduo Xr Dapaglifloz Propaned/Metformin | Brand | 85 | $53,455 | |
| Jardiance Empagliflozin | Brand | 67 | $43,615 | |
| Synthroid Levothyroxine Sodium | Brand | 775 | $41,138 | |
| Janumet Xr Sitagliptin Phos/Metformin Hcl | Brand | 39 | $26,949 | |
| Mounjaro Tirzepatide | Brand | 22 | $23,748 | |
| Glyxambi Empagliflozin/Linagliptin | Brand | 22 | $20,441 |
The 10 drugs with the highest cost, of 54 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| JARDIANCE |
|
$189 | 67 | — |
| MOUNJARO |
|
$175 | 22 | — |
| FARXIGA |
|
$125 | 31 | — |
| RYBELSUS |
|
$32 | — | — |
| Ozempic |
|
$32 | 164 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
341 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in Puerto Rico
Jose Garcia Mateo
Endocrinology, Diabetes & Metabolism · Ponce, PR
Manuel Alegre-Hernandez
Endocrinology, Diabetes & Metabolism · San Juan, PR
Monica Ortiz-Rivera
Endocrinology, Diabetes & Metabolism · San Juan, PR
Alex Gonzalez Bossolo
Endocrinology, Diabetes & Metabolism · San Juan, PR
Michelle Mangual Garcia
Endocrinology, Diabetes & Metabolism · San Juan, PR
Meliza Martinez Rodriguez
Endocrinology, Diabetes & Metabolism · San Juan, PR
Related records
Endocrinology, Diabetes & Metabolism in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.